Opus Genetics, Inc.
No enriched coverage for $IRD in the last 7 days.
Foundation Fighting Blindness Retinal Degeneration Fund sold 556,000 shares of Opus Genetics, Inc. (IRD) at $4.96 ($2.76M total) on 2026-09-30. Filed jointly with Foundation Fighting Blindness, Inc. (Director).
Opus Genetics (NASDAQ: IRD) reported that all five participants in its BIRD-1 trial showed clinically meaningful improvements in visual function. The Phase 1/2 trial included patients with Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy, with no serious adverse events. The company is considering Phase 3 planning, with FDA alignment on potential endpoints. Higher-dose cohort dosing is expected to finish in Q4 2026, with topline results in Q2 2027.
Opus Genetics, Inc. (IRD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looki
Recent IRD coverage spans technology, earnings and insider activity.
In the last 30 days, IRD insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($2.9M). The most active reporter was Gagnon Robert E., Chief Financial Officer, with 1 filing. 50% of those filings were made under pre-arranged Rule 10b5-1 plans.
Foundation Fighting Blindness Retinal Degeneration Fund sold 556,000 shares of Opus Genetics, Inc. (IRD) at $4.96 ($2.76M total) on 2026-09-30. Filed jointly with Foundation Fighting Blindness, Inc. (Director).
Early efficacy signals may boost investor optimism but limited sample size keeps risk high.
Positive early‑stage data may reduce perceived risk and support near‑term price appreciation.
Positive trial results suggest potential Phase 3, likely boosting near‑term demand.
Positive early‑stage data may drive further upside as investors anticipate later‑stage trials.
AlphAI scores every news story that mentions IRD with an AI model for sentiment and relevance, and aggregates insider trades from Opus Genetics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Foundation Fighting Blindness Retinal Degeneration Fund sold 556,000 shares of Opus Genetics, Inc. (IRD) at $4.96 ($2.76M total) on 2026-09-30. Filed jointly with Foundation Fighting Blindness, Inc. (Director).
1 min readOpus Genetics (NASDAQ: IRD) reported that all five participants in its BIRD-1 trial showed clinically meaningful improvements in visual function. The Phase 1/2 trial included patients with Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy, with no serious adverse events. The company is considering Phase 3 planning, with FDA alignment on potential endpoints. Higher-dose cohort dosing is expected to finish in Q4 2026, with topline results in Q2 2027.
2 min readOpus Genetics, Inc. (IRD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looki
1 min readOpus Genetics (IRD) rose 27% after positive clinical trial data. Quantum (QNTM) gained 10% with FDA Phase 2 trial clearance. Pulse Biosciences (PLSE) surged 15% without specific news. Decoy Therapeutics (DCOY) and ONWARD Medical (ONWD.BR) also traded higher on updates.
3 min readOpus Genetics (IRD) shares rose 38% to $5.99 after positive 3- and 6-month results from its Phase 1/2 BIRD-1 trial for OPGx-BEST1. All five patients showed visual function improvements, with structural improvements in four. The treatment had a favorable safety profile. Volume reached 32.46 million shares, significantly above its average.
2 min readOpus Genetics (IRD) reported positive 3- and 6-month data from its Phase 1/2 trial of OPGx-BEST1 for retinal diseases, showing improvements in visual function and structure. The FDA aligned on potential endpoints for a pivotal trial. The company plans to start a Phase 3 trial in 2027. IRD stock is up 19.82% in pre-market trading.
2 min readCaleres Inc (CAL) reported Q2 earnings of $0.47 per share, beating estimates of $0.37, and raised FY26 EPS guidance. Shares rose 14.4% to $13.76. Other companies like Opus Genetics (IRD), Signet Jewelers (SIG), and Flotek Industries (FTK) also saw significant gains due to positive updates.
2 min readOpus Genetics (Nasdaq: IRD) reported Q2 2026 results for the quarter ended June 30, 2026. Cash was $88.8 million, expected to fund operations into 2029. Revenue fell to $0.8 million from $2.9 million. R&D rose to $11.2 million. Net loss was $8.1 million. The company also updated clinical timelines for OPGx-BEST1, OPGx-LCA5, and other programs.
6 min readOpus Genetics, Inc. (IRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update OPGx-BEST1 Cohort 1 Topline Data Expected in Second Week of September 2026 Enrollment Completed in LCA5 Registrational Trial with Dosing Planned for Q4 2026 RDH12, MERTK a
6 min readOpus Genetics (Nasdaq: IRD) updated its OPGx-BEST1 Phase 1/2 trial (BIRD-1) for BEST1-associated inherited retinal diseases. Cohort 1 enrollment (5 participants) is complete, with Month 3 data expected in the second week of September 2026. The company plans to present at EURETINA in October 2026 and submit Month 3 results to the FDA for next steps.
4 min read
